Amdocs (NASDAQ:DOX – Get Free Report) and Black Titan (NASDAQ:BTTC – Get Free Report) are both technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Amdocs and Black Titan”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amdocs | $4.53 billion | 1.48 | $564.70 million | $4.20 | 14.84 |
| Black Titan | $180,000.00 | 31.17 | -$4.71 million | ($2.95) | -0.18 |
Institutional & Insider Ownership
92.0% of Amdocs shares are owned by institutional investors. 15.4% of Amdocs shares are owned by insiders. Comparatively, 0.7% of Black Titan shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Amdocs has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Black Titan has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.
Profitability
This table compares Amdocs and Black Titan’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amdocs | 9.75% | 20.28% | 10.94% |
| Black Titan | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings and price targets for Amdocs and Black Titan, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amdocs | 1 | 3 | 3 | 0 | 2.29 |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
Amdocs presently has a consensus target price of $86.67, suggesting a potential upside of 39.09%. Given Amdocs’ stronger consensus rating and higher possible upside, research analysts plainly believe Amdocs is more favorable than Black Titan.
Summary
Amdocs beats Black Titan on 12 of the 14 factors compared between the two stocks.
About Amdocs
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers. It also offers AI-powered, cloud-native, and home operating systems; data intelligence solutions and applications; end-to-end application development and maintenance services; and ongoing maintenance services. In addition, the company provides a line of services designed for various stages of a service provider’s lifecycle includes consulting, delivery, quality engineering, operations, systems integration, network services, experience-driven services, data, cloud, and content services; managed services comprising application development, modernization and maintenance, IT and infrastructure services, testing and professional services that are designed to assist customers in the selection, implementation, operation, management, and maintenance of IT systems. It serves to the communications, entertainment, and media industry service providers, as well as mobile virtual network operators. Amdocs Limited was founded in 1988 and is headquartered in Saint Louis, Missouri.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
